Contineum Therapeutics — Third Quarter 2026 Earnings Summary

Contineum Therapeutics reported a net loss of $18.7 million for the third quarter of 2026, driven by a 45 percent increase in research and development expenses to $16.0 million. The company's cash, cash equivalents, and marketable securities totaled $244.5 million as of September 30, 2026, providing a projected runway through mid-2029. PIPE-791, an LPA1 receptor antagonist, is currently being evaluated in the global Phase 2 PROPEL-IPF trial for idiopathic pulmonary fibrosis, which has enrolled over 100 sites across 16 countries.